34 results about "Pbsc mobilization" patented technology

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.

A method for haematopoietic stem and / or progenitor cell (HSPC) transplantation in a subject in need thereof, comprising the steps: (a) administering one or more HSPC mobiliser to the subject to mobilise the subject's endogenous HSPCs; and (b) administering a population of HSPCs to the subject.

The invention discloses a system and a device for measuring the cardiopulmonary endurance of an adult, and relates to the technical field of cardiopulmonary endurance measurement. The system comprises a power vehicle, a heart rate acquisition module, a data processing module, a motion control and voice guide module, a load regulation and control module, a result output and data management module, a safety monitoring and stopping module and a user interaction module, and the power vehicle comprises a positioning base, a supporting seat, a vehicle frame, a counting and power utilization mechanism and a measurement and power recovery mechanism. A stable and controllable physical exercise platform and an adjustable load system are provided, a heart rate collection module collects heart rate data of a subject in the resting and exercise process in real time, and the heart rate data serve as a VOmax estimation core basis. And data of more dimensions can be incorporated during formula calculation of the maximum oxygen uptake, so that the effect is better.

The present invention provides a personalized rehabilitation training method and system based on state monitoring, which relates to the field of rehabilitation training technology. The method includes: obtaining electromyographic amplitude, root mean square, and spectrum median, calculating the rate of change, monitoring muscle fiber mobilization, blood oxygen, lactate metabolism, and heart rate variability, extracting the rate of change of joint angles and moment of inertia, and obtaining a training load reference value. In the present invention, by real-time monitoring and analysis of multiple physiological parameters including electromyographic signals, blood oxygen saturation, and heart rate variability, an accurate training load reference value is established to improve the accuracy of neuromuscular coordination assessment. By comparing the rate of change of electromyographic signals in short and long time windows, the training load is accurately adjusted to reduce fatigue risk. By real-time adjustment of the rehabilitation robot's motion trajectory and optimization of the training rhythm, it is ensured that the training intensity matches the individual's metabolic capacity, and dynamic matching and personalized adjustment of the training plan are achieved, effectively improving the safety and effectiveness of training.

The present invention relates to a combination therapy and combination product for mobilizing large numbers of hematopoietic stem cells in the blood, comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof; a method for collecting large numbers of mobilized hematopoietic stem cells, comprising a step of separating a blood fraction containing mobilized hematopoietic stem cells from peripheral blood obtained from an individual to whom substance P and AMD3100 or a pharmaceutically acceptable salt thereof have been sequentially administered; and the use of a formulation comprising substance P and AMD3100 or a pharmaceutically acceptable salt thereof for mobilizing large numbers of hematopoietic stem cells in the blood.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The present application relates to the field of biological medicine, in particular to a tumor treatment platform based on endogenous and exogenous zinc overload strategy, a preparation method and application. For the treatment platform, it comprises an acid-sensitive carrier, zinc ions and a sound-sensitive organic ligand; the sound-sensitive organic ligand can generate reactive oxygen under ultrasonic irradiation; the sound-sensitive organic ligand and the zinc ions are connected by a coordination bond to form a metal-organic complex; and the metal-organic complex is loaded on the acid-sensitive carrier. The present application proposes a tumor treatment strategy of "endogenous-exogenous synergy", combines "exogenous Zn 2+ " delivery with "endogenous Zn 2+ " mobilization, successfully induces "Zn 2+ overload" in cells through the synergistic effect of the two, realizes the precise, efficient and controllable induction of local Zn 2+ overload in tumors, and improves the effectiveness of pyroptosis. Through the present application, the limitations of traditional methods in controllability, efficacy and safety are overcome.

Disclosed herein are methods of mobilizing hematopoietic stem and progenitor cells (HSPC) in a subject in need thereof, the methods include administering one or both of (1) an inhibitor of the polymerization of hemoglobin S and (2) a P-selectin or E-selectin inhibitor, prior to administering a hematopoietic stem cell mobilizing agent.

A method of mobilizing hematopoietic precursor cells from the bone marrow to the peripheral blood of a subject is provided. The method comprising (a) administering to the subject an effective amount of natalizumab; and (b) administering to the subject an effective amount of a CXCR4 inhibitor, wherein step (b) is effected at least 48 hours following step (a). Also provided are uses of such mobilization procedures in cell collection and in treatment.

A method of mobilizing CD34 + cells in a subject suffering from sickle cell disease (SCD) is provided. The method comprises the following steps: a therapeutically effective amount of CXCR4 inhibitory peptide shown as SEQ ID NO: 1 and a therapeutically effective amount of natazumab are applied to a subject, and the natazumab and the CXCR4 inhibitory peptide are sequentially applied. Also provided is the use of mobilized cells for subsequent treatment of SCD in gene therapy.

Means, methods, and compositions of matter for accelerating hematopoiesis and / or stem cell engraftment through induction of senolysis and / or deactivation of senescent cells. Senolytic agents can be administered together with hematopoietic growth factors. Resistance to stem cell mobilization can be accomplished by removal of senescent cells through senolytic and / or senescence inactivating approaches.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The invention designs a novel double-target peptide agonist targeting peripheral Kappa and Mu opioid receptors or pharmaceutically acceptable salts of the double-target peptide agonist, namely, chimeric peptides MKOP001 and MKOP002 are newly constructed on the basis of a DN-9 and dynorphin efficient analogue [des-Arg7] Dyn A (1-11)-NH2 sequence. An in-vitro calcium mobilization experiment and an acute analgesic experiment show that the brand new peptide agonists MKOP001 and MKOP002 can simultaneously activate Kappa and Mu opioid receptors and generate efficient analgesic activity. In addition, further research shows that both the MKOP001 and the MKOP002 can generate a remarkable itching relieving effect. Therefore, the peripheral restrictive Kappa and Mu opioid receptor double-target peptide molecules MKOP001 and MKOP002 or pharmaceutically acceptable salts thereof have very high application value in the aspect of preparing high-efficiency and low-side-effect analgesic or antipruritic drugs.

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron / systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and / or improvement of cognitive functions in a subject in need thereof.

The invention relates to the technical field of biological medicine, and discloses application of paeoniflorin in preparation of medicine for preventing or treating acute graft versus host disease. The invention can promote hematopoietic recovery to regulate immune homeostasis. The donor hematopoietic stem cells are mobilized, glycometabolism, fatty acid metabolism and amino acid metabolism pathways of the hematopoietic stem cells are activated in a targeted manner, the activity of the transplanted hematopoietic stem cells is enhanced, and hematopoietic reconstruction is accelerated. The application disclosed by the invention can play a role in preventing or treating aGVHD by inhibiting amplification and activation of donor T cells, inhibiting release of inflammatory cytokines / chemotactic factors, improving the level of anti-inflammatory cytokines, relieving intestinal injury, balancing intestinal flora and other mechanisms.

The present disclosure provides therapeutic agents comprising VLA-4 (a4b1) and a4b?inhibiting agents defined herein. Methods of using the therapeutic agents are also provided. The present disclosure further provides combinations of a VLA-4 inhibitor and one or more agents which interact with a chemokine receptor or chemokine receptors, and methods of use thereof. In some embodiments, the disclosed combinations may be used in a method of mobilizing hematopoietic stem cells. In some embodiments, the disclosed methods may be used in the treatment of a condition that requires the collection of hematopoietic stem cells for transfusions or in chemotherapy. The present disclosure further provides methods of treating a patient comprising administering an agent which interacts with a chemokine such as G-CSF, plerixafor, BL-8040 (Motixafortide), or Crop and VLA-4 inhibitors.

The present invention relates to a method and composition for mobilizing cells from a subject by blocking CXCR4, beta-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are hematopoietic stem cells. In some embodiments, the method further comprises the administration of G-CSF. The present invention also relates to a treatment method, a method for qualifying a subject for treatment, and a method for preparing a subject for treatment by blocking CXCR4, beta-adrenergic receptors, GPCRs, or any combination thereof. In some embodiments, the cells are hematopoietic stem cells. In some embodiments, the treatment is for cancer. In some embodiments, CXCR4 is GPC-100. In some embodiments, the method further comprises the administration of G-CSF.

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.

The invention relates to a memory-enhancing NK cell (EM-NK) culture medium and application thereof. The synergistic memory type NK cell (EM-NK) culture medium comprises a cell factor and antibody combination and mobilized peripheral blood plasma. According to the invention, the plasma component of the mobilized PBMC is added into a culture system and contains bioactive substances such as various cytokines and exosomes, so that the proliferation and activity enabling of cells are facilitated, and the stability and effectiveness in the preparation process are kept. Meanwhile, due to the fact that a specific cell factor and antibody combination is added into the culture medium, the purity of the obtained synergistic memory type NK cells is obviously improved, and meanwhile the killing rate is also obviously improved.

The present invention provides improved devices for biopsy, aspiration, stem cell acquisition, and methods of using the same. The devices balance aspiration with concurrent infusion to manage changes in pressure at the site of biopsy. The present invention can be adapted for any biopsy, aspiration, or cell harvest procedure, including adipose tissue aspiration and bone marrow aspiration (BMA). In particular, the present invention limits patient pain, prevents blood contamination, and increases cell mobilization, such as improved stem cell yields with intraosseous (10) pharmacological mobilization of stem cells during a BMA procedure, and with improved stem cell yields using pharmacological mobilization of stem cells from fat. The pharmacological mobilization of cells allows the harvest of cells from a biopsy many fold larger than existing methods.

The invention discloses a PBSC and PRP mixed product obtaining method and system based on synchronous collection, and the method comprises the steps: collecting basic information of a patient, treatment appeals and target specifications of a mixed product, selecting adaptive blood cell separation equipment and a sterile pipeline under the condition that a mobilizing agent is not used, and carrying out the collection of the mixed product; and a closed loop circulation system is constructed, and preparation setting is completed for synchronous collection of PBSC and PRP mixed products. After the program is started, blood components and fluid-physiological data are collected in real time through the sensing module and transmitted to the control unit. A multi-target control model is constructed based on improved particle swarm optimization, and parameters such as the centrifugal rotating speed are adjusted every 2 seconds under the constraint that component concentration reaches the standard and impurity residues meet the standard. After the peripheral blood is centrifuged and layered, the PBSC and the PRP are synchronously mixed, and red blood cells and redundant plasma are transfused back. Parameters are compared in real time to calculate deviation, and iteration adjustment is carried out when the threshold value exceeds; if the physiological parameters are abnormal, the flow rate is adjusted or an alarm is given, collection and quality inspection are terminated after the product reaches the standard, and if the product is qualified, a target mixed product is obtained. And the preparation safety and reliability are improved.

The invention discloses a blood use priority management system and a supply and demand balance implementation method based on a medical system. The system adopts a layered architecture design, and realizes blood resource allocation, priority blood use whole-process management, emergency blood donation mobilization and multi-system data intercommunication by integrating business system data of a medical member unit and a blood collection and supply mechanism; according to the implementation method, a closed-loop management system of appointment-recruitment-collection-supply is constructed through mechanisms such as dynamic quota regulation and control, accurate cashing of preferential blood utilization rights and intellectual blood donor recruitment linkage, the blood resource utilization efficiency is improved, the blood donation behavior is stimulated, and finally the dynamic balance of blood supply and demand is achieved. The blood resource allocation can be effectively optimized, the first-aid blood use and priority blood use requirements are guaranteed, and the intelligent level of regional blood management is improved.

Using adults stem cells (ASC) including hematopoietic cell (HSC), endothelial progenitor cells and mesenchymal (MSC) stem cells; mobilizing ASC cells into the vascular system using a collection system of one of: (i) an apheresis. (ii) bone marrow; or (iii) direct collection of ASC from the peripheral blood; providing the ASC with a cryopreservation conservation container of about minus 80 degrees centigrade collecting the ASC for defrosting and placed in a sterile container; reprogramming stem cells (RSC) including at least one of (i) RSC by methylation patterns of DNA such as JMJD3 and HDAC; (ii) RSC by acetylation patterns of DNA such as HDAC; (iii) epigenetic programming with a protein of interest (ncRNA); using vectors of AAV or CMV to transfer to specific genes to provide proteins to enlarge physical conditions to lost during the aging process.

Disclosed are hydrogel matrices for use in recruiting and reprogramming CAR T cells, CAR NK cells, CAR NK T cells, CAR macrophages, tumor-infiltrating NK cells, tumor-infiltrating lymphocytes, and bone marrow-infiltrating lymphocytes.

This invention relates to methods and compositions directed to mobilizing a cell in a subject by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is a stem cell. In some embodiments, the cell is an immune cell.

Described herein are compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a subject, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and / or therapeutic use. In accordance with the composition and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others.

This invention relates to the application of norbaicalin (NWG) as an active ingredient, belonging to the fields of biomedicine and heavy metal toxicity intervention technology. Norbaicalin (NWG) is used as an active ingredient in the preparation of drugs that inhibit bone lead mobilization during pregnancy and lactation, improve bone metabolic disorders and bone microstructural damage caused by lead exposure. The advantages are: NWG first effectively inhibits osteoclast activation, thereby significantly regulating bone metabolism-related markers, manifested as upregulation of bone formation indicators and downregulation of bone resorption indicators, reversing lead exposure-induced bone metabolic imbalance and exerting a bone-protective effect; NWG intervention can significantly improve the morphology of distal femoral trabeculae, increase the number and thickness of trabeculae, reduce gaps, decrease the number of TRAP-positive osteoclasts, and effectively repair lead-induced bone microstructural damage; thus achieving precise inhibition of bone lead mobilization, providing a new scientific basis and application strategy for the risk prevention and control of endogenous lead re-exposure during pregnancy and lactation.

The present disclosure provides methods for treating various diseases or disorders, down-regulating and up-regulating various pathways, and mobilizing stem cells and / or immune cells in a patient comprising administering a pharmaceutical composition to a subject. In particular embodiments, the pharmaceutical composition comprises (a) a stem cell mobilizing agent and (b) an immunosuppressive or non-immunosuppressive FK binding protein ligand in a low or sub-immunosuppressive amount. The methods of the present disclosure may comprise administering a pharmaceutical composition by pathways and dosing regimens as disclosed herein.

This invention relates to methods and compositions directed to mobilizing a cell in a subject by blocking CXCR4, a beta-adrenergic receptor, a GPCR, or any combination thereof. In some embodiments, the cell is an immune cell. In some embodiments, the cell is a lymphocyte.